MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval
MannKind announced that the FDA has approved Afrezza for use in children and adolescents aged 6 and older with diabetes. Management will host a conference call today at 4:30 p.m. ET to discuss the approval and its implications for the company's diabetes franchise.
Key figures
- Drug Name
- Afrezza
- Target population
- children and adolescents aged 6 and older living with diabetes
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.